Abstract
Introduction: Although several approaches have been studied for treating wet age-related macular degeneration (w-AMD), currently, the most effective strategy in the management of this visual disorder is represented by anti-VEGF drugs. Among them, ranibizumab (RBZ) is widely adopted in clinical practice for treating w-AMD. Areas covered: VEGF (vascular endothelial growth factor) is a hypoxia-induced growth factor promoting neoangiogenesis, which has been correlated to the pathogenesis of w-AMD. RBZ is a humanized, recombinant, monoclonal antibody fragment (Fab), which binds all the isoform of VEGF-A and, therefore, exerts an inhibitory activity on the growth of new pathological vessels leading to the reabsorption of VEGF-related macular edema. The pivotal trials ANCHOR and MARINA revealed its clinical efficacy and good safety profile for treating w-AMD, leading ultimately to its FDA approval. Further trials have analyzed the best dosage and regimen modality, reporting RBZ at 0.5 mg with a ‘pro re nata’ regimen (PRN) to be non-inferior to the 0.5 mg formulation administered monthly. The treat-to-extend (TAE) regimen has also been investigated, demonstrating encouraging results in terms of clinical efficacy and nonetheless, it was proven to be a well-tolerated option with the possibility of reducing the treatment burden for the patients. Conclusions: RBZ has been proven to be an effective anti-VEGF agent for treating w-AMD; however, more optimal therapeutic regimens and drug delivery systems are being investigated in order to improve patients’ compliance and treatment burden.
| Original language | English |
|---|---|
| Pages (from-to) | 735-751 |
| Number of pages | 17 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 19 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2019 |
Fingerprint
Keywords
- angiogenesis
- macular degeneration
- OCT
- Ranibizumab
- retina
- targeted therapy
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry
Cite this
Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. / Ferro Desideri, Lorenzo; Barra, Fabio; Ferrero, Simone; Traverso, Carlo Enrico; Nicolò, Massimo.
In: Expert Opinion on Biological Therapy, Vol. 19, No. 8, 01.08.2019, p. 735-751.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration
AU - Ferro Desideri, Lorenzo
AU - Barra, Fabio
AU - Ferrero, Simone
AU - Traverso, Carlo Enrico
AU - Nicolò, Massimo
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Introduction: Although several approaches have been studied for treating wet age-related macular degeneration (w-AMD), currently, the most effective strategy in the management of this visual disorder is represented by anti-VEGF drugs. Among them, ranibizumab (RBZ) is widely adopted in clinical practice for treating w-AMD. Areas covered: VEGF (vascular endothelial growth factor) is a hypoxia-induced growth factor promoting neoangiogenesis, which has been correlated to the pathogenesis of w-AMD. RBZ is a humanized, recombinant, monoclonal antibody fragment (Fab), which binds all the isoform of VEGF-A and, therefore, exerts an inhibitory activity on the growth of new pathological vessels leading to the reabsorption of VEGF-related macular edema. The pivotal trials ANCHOR and MARINA revealed its clinical efficacy and good safety profile for treating w-AMD, leading ultimately to its FDA approval. Further trials have analyzed the best dosage and regimen modality, reporting RBZ at 0.5 mg with a ‘pro re nata’ regimen (PRN) to be non-inferior to the 0.5 mg formulation administered monthly. The treat-to-extend (TAE) regimen has also been investigated, demonstrating encouraging results in terms of clinical efficacy and nonetheless, it was proven to be a well-tolerated option with the possibility of reducing the treatment burden for the patients. Conclusions: RBZ has been proven to be an effective anti-VEGF agent for treating w-AMD; however, more optimal therapeutic regimens and drug delivery systems are being investigated in order to improve patients’ compliance and treatment burden.
AB - Introduction: Although several approaches have been studied for treating wet age-related macular degeneration (w-AMD), currently, the most effective strategy in the management of this visual disorder is represented by anti-VEGF drugs. Among them, ranibizumab (RBZ) is widely adopted in clinical practice for treating w-AMD. Areas covered: VEGF (vascular endothelial growth factor) is a hypoxia-induced growth factor promoting neoangiogenesis, which has been correlated to the pathogenesis of w-AMD. RBZ is a humanized, recombinant, monoclonal antibody fragment (Fab), which binds all the isoform of VEGF-A and, therefore, exerts an inhibitory activity on the growth of new pathological vessels leading to the reabsorption of VEGF-related macular edema. The pivotal trials ANCHOR and MARINA revealed its clinical efficacy and good safety profile for treating w-AMD, leading ultimately to its FDA approval. Further trials have analyzed the best dosage and regimen modality, reporting RBZ at 0.5 mg with a ‘pro re nata’ regimen (PRN) to be non-inferior to the 0.5 mg formulation administered monthly. The treat-to-extend (TAE) regimen has also been investigated, demonstrating encouraging results in terms of clinical efficacy and nonetheless, it was proven to be a well-tolerated option with the possibility of reducing the treatment burden for the patients. Conclusions: RBZ has been proven to be an effective anti-VEGF agent for treating w-AMD; however, more optimal therapeutic regimens and drug delivery systems are being investigated in order to improve patients’ compliance and treatment burden.
KW - angiogenesis
KW - macular degeneration
KW - OCT
KW - Ranibizumab
KW - retina
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85067582830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067582830&partnerID=8YFLogxK
U2 - 10.1080/14712598.2019.1627322
DO - 10.1080/14712598.2019.1627322
M3 - Article
C2 - 31180279
AN - SCOPUS:85067582830
VL - 19
SP - 735
EP - 751
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 8
ER -